Less Ads, More Data, More Tools Register for FREE

Pin to quick picksM P Evans Regulatory News (MPE)

Share Price Information for M P Evans (MPE)

Share Price is delayed by 15 minutes
Get Live Data
1,502.00    -48.00 (-3.10%)
Bid:
1,494.00
Ask:
1,498.00
Spread: 4.00 (0.268%)
Market Cap: £783.50m
MPE Live PriceLast checked at - London Stock Exchange

Intraday M P Evans Share Chart

Director/PDMR Shareholding

23 Jan 2026 07:00

RNS Number : 0393Q
M. P. Evans Group PLC
23 January 2026
 

M.P. Evans Group PLC

(the "Company" or "M.P. Evans")

 

Director/PDMR Shareholding

 

M.P. Evans Group PLC, a producer of sustainable Indonesian palm oil, announces that on 22 January 2026 it was notified of the exercise of share options under the M.P. Evans Group PLC Long Term Incentive Scheme by Mr. M H Coulson, the chief executive. Mr. M H Coulson exercised share options over 18,000 shares of 10p each in the capital of the Company ("Shares") that were granted at nil cost per Share and were due to expire on 15 January 2033. Simultaneously, Mr. M H Coulson sold 8,450 Shares at £12.385 per Share in order to fund the tax and National Insurance liabilities resulting from the exercise of the share options. In addition, Mr M H Coulson transferred the remaining 9,550 Shares to his wife Mrs. N Coulson.

 

As a result of this exercise of options, Mr. M H Coulson's attributable shareholding is now 52,800 Shares, representing approximately 0.10% of the Company's issued share capital.

 

This award was satisfied out of Shares held by the Trustee of the M.P. Evans Group 2018 Employees' Benefit Trust. Therefore, the total number of Shares with voting rights in the Company remains at 52,256,292.This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The notification below, provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.

 

 1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Matthew Harrison Coulson

 

2

Reason for the notification

 

a)

Position/status

 

Chief executive

b)

Initial notification/Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

M.P. Evans Group PLC

b)

LEI

 2138003IBXJUCR4SZG26

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Shares of 10 pence per share in M.P. Evans Group PLC ("Shares").

 

Identification code: ISIN GB007538100

 

b)

Nature of the transaction

a) Exercise of options over Shares

b) Sale of shares

c) Transfer of shares

 

c)

Price(s) and volume(s)

 

a) Price: Nil Volume: 18,000

b) Price:1238.5 pence Volume: 8,450

c) Price: Nil Volume: 9,550

 

 

d)

Aggregated information

 

a) N/A

b) N/A

c) N/A

 

Date of transaction

22 January 2026

 

f)

Place of transaction

a) Outside a trading venue

b) London Stock Exchange (XLON): AIM

c) Outside a trading venue

 

23 January 2026

 

 

Enquiries:

 

M.P. Evans Group PLC

Tel: +44 (0) 1892 516333

Peter Hadsley-Chaplin, chairman

Matthew Coulson, chief executive

Luke Shaw, chief financial officer

Cavendish Capital Markets (Nomad and joint broker)

Tel: +44 (0) 20 7220 0500

Matt Goode, George Lawson (Corporate finance)

Tim Redfern, Harriet Ward (ECM)

Canaccord Genuity Limited (Joint broker)

Tel: +44 (0) 20 7523 4500

Henry Fitzgerald-O'Connor, George Grainger

Alma Strategic Communications (Financial PR)

Tel: +44 (0)20 3405 0205

Rebecca Sanders-Hewett, Josh Royston, David Ison

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEMFWEEMSEEF
Date   Source Headline
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:30 amRNSTotal Voting Rights
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTransaction in Own Shares
28th May 20267:00 amRNSTransaction in Own Shares
26th May 20262:42 pmRNSShare Buyback Programme
20th May 202611:26 amRNSIndonesian commodity exporting
12th May 20262:52 pmRNSAGM Arrangements
1st Apr 20265:40 pmRNS2025 Annual Report
26th Mar 202610:16 amRNSDirector/PDMR Shareholding
24th Mar 20267:00 amRNSFinal Results 2025
5th Mar 20267:00 amRNSNotice of Results
23rd Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Jan 20267:00 amRNS2025 Crop and production
16th Jan 20261:05 pmRNSDirector/PDMR Shareholding
6th Jan 20267:00 amRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
11th Dec 202512:58 pmRNSPublication of 2024 ESG report
2nd Dec 20251:14 pmRNSCompany update
1st Dec 20257:00 amRNSAppointment of joint broker
10th Nov 20257:00 amRNSStrong pricing during second half of 2025
28th Oct 20255:33 pmRNSHolding(s) in Company
22nd Sep 20253:26 pmRNSAIM Rule 20
15th Sep 20257:00 amRNSHalf-year Report
27th Aug 20257:00 amRNSNotice of interim results & investor presentation
29th Jul 20257:00 amRNSPublication of TCFD report
24th Jul 20257:00 amRNS2025 H1 crop and production
14th Jul 202510:07 amRNSAcquisition
7th Jul 20254:54 pmRNSDirector/PDMR Shareholding
30th Jun 20254:30 pmRNSTotal Voting Rights
25th Jun 202511:18 amRNSIssue of Equity
18th Jun 20257:00 amRNSShare buyback programme
13th Jun 20251:45 pmRNSResult of AGM
13th Jun 20257:00 amRNSAGM Statement
12th Jun 20254:50 pmRNSAppointment to board roles
5th Jun 20257:00 amRNSAGM update
14th May 20257:00 amRNSDirectorate Change
22nd Apr 20255:33 pmRNSDirector/PDMR Shareholding
16th Apr 202511:00 amRNSAcquisition
31st Mar 20254:02 pmRNSPosting of Annual Report
25th Mar 20257:00 amRNSFinal Results
21st Mar 20257:00 amRNSDirector retirement
5th Mar 20257:00 amRNSNotice of Results and investor presentation
20th Jan 20253:05 pmRNSDirector/PDMR Shareholding
20th Jan 20257:00 amRNSCrop and production
2nd Jan 202511:31 amRNSDirector/PDMR Shareholding
2nd Jan 20257:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.